Abbott Laboratories banner

Abbott Laboratories
NYSE:ABT

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
NYSE:ABT
Watchlist
Price: 92.365 USD -1.59%
Market Cap: $160.5B

EV/FCFF

21.8
Current
37%
Cheaper
vs 3-y average of 34.6

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
21.8
=
Enterprise Value
$166.8B
/
Free Cash Flow to Firm
$7.4B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
21.8
=
Enterprise Value
$166.8B
/
Free Cash Flow to Firm
$7.4B

Valuation Scenarios

Abbott Laboratories is trading below its 3-year average

If EV/FCFF returns to its 3-Year Average (34.6), the stock would be worth $146.54 (59% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+59%
Average Upside
27%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 21.8 $92.37
0%
3-Year Average 34.6 $146.54
+59%
5-Year Average 29.6 $125.09
+35%
Industry Average 23 $97.51
+6%
Country Average 23.2 $98.3
+6%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
US
Abbott Laboratories
NYSE:ABT
163B USD 21.8 25.6
US
Intuitive Surgical Inc
NASDAQ:ISRG
165.7B USD 62.1 56.3
US
Stryker Corp
NYSE:SYK
122.9B USD 30.7 37.1
IE
Medtronic PLC
NYSE:MDT
105.1B USD 22.6 22.2
US
Boston Scientific Corp
NYSE:BSX
86.7B USD 25.5 23.6
US
Edwards Lifesciences Corp
NYSE:EW
47.8B USD 32.9 43.4
DE
Siemens Healthineers AG
XETRA:SHL
39.8B EUR 20.5 18.1
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.3B USD 42.2 41.2
US
Becton Dickinson and Co
NYSE:BDX
42.6B USD 22 23.8
US
Resmed Inc
NYSE:RMD
31.6B USD 17 21
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
31.2B USD 21.7 13.2

Market Distribution

In line with most companies in the United States of America
Percentile
47th
Based on 8 393 companies
47th percentile
21.8
Low
0 — 15.4
Typical Range
15.4 — 35.1
High
35.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 15.4
Median 23.2
70th Percentile 35.1
Max 3 178 983.5

Abbott Laboratories
Glance View

Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.

ABT Intrinsic Value
100.898 USD
Undervaluation 8%
Intrinsic Value
Price $92.365
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett